Ashkar, A., El-Hosseiny, L., Abu Zahra, F., Abd El-Samee, N., Barakat, A., Elgohary, S., Badawy, A. (2020). Potential Therapeutic Effect of Allogenic Mesenchymal Stem Cells on Chronic Cerebral Murine Toxoplasmosis. Afro-Egyptian Journal of Infectious and Endemic Diseases, 10(2), 129-140. doi: 10.21608/aeji.2020.23818.1051
Ayman Mohamed Ashkar; Laila Mohammed El-Hosseiny; Fatma Abdelkarim Abu Zahra; Nermeen Mohammed Abd El-Samee; Ashraf Mohammed Barakat; Shimaa Abdelraouf Elgohary; Abeer Fathy Badawy. "Potential Therapeutic Effect of Allogenic Mesenchymal Stem Cells on Chronic Cerebral Murine Toxoplasmosis". Afro-Egyptian Journal of Infectious and Endemic Diseases, 10, 2, 2020, 129-140. doi: 10.21608/aeji.2020.23818.1051
Ashkar, A., El-Hosseiny, L., Abu Zahra, F., Abd El-Samee, N., Barakat, A., Elgohary, S., Badawy, A. (2020). 'Potential Therapeutic Effect of Allogenic Mesenchymal Stem Cells on Chronic Cerebral Murine Toxoplasmosis', Afro-Egyptian Journal of Infectious and Endemic Diseases, 10(2), pp. 129-140. doi: 10.21608/aeji.2020.23818.1051
Ashkar, A., El-Hosseiny, L., Abu Zahra, F., Abd El-Samee, N., Barakat, A., Elgohary, S., Badawy, A. Potential Therapeutic Effect of Allogenic Mesenchymal Stem Cells on Chronic Cerebral Murine Toxoplasmosis. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2020; 10(2): 129-140. doi: 10.21608/aeji.2020.23818.1051
Potential Therapeutic Effect of Allogenic Mesenchymal Stem Cells on Chronic Cerebral Murine Toxoplasmosis
1Department of Medical Parasitology, Faculty of Medicine, Ain Shams University, Egypt and Department of Basic Medical Science, College of Medicine, University of Bisha, KSA
2Department of Medical Parasitology, Faculty of Medicine, Ain Shams University, Egypt.
3Medical Research Centre, Faculty of Medicine - Ain Shams University, Egypt.
4Department of Zoonotic Diseases,National Research Center,Egypt
5Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abstract
Background and Aim: Toxoplasma infection is mainly latent and cause severe disease only if reactivation occurs especially for brain cysts. This study aimed to evaluate the therapeutic effect of BM-MSCs on murine chronic toxoplasmosis experimental model. Methods: Female Swiss albino mice (n=100) were divided into 5 groups (20 mice each). Group I (infected, injected with BM-MSCs); Group II (infected, treated with BM-MSCs and Spiramycin-Metronidazole); Group III (infected, treated with Spiramycin-Metronidazole); Group IV (infection control) and Group V (non infected, injected with BM-MSCs). Results: In Regarding the mean Toxoplasma brain cyst count, after 7 and 14 days, group I was significantly lower than group II, higher than group III and non-statistically different from group IV. Group II was significantly higher than in groups III and IV. Group III showed a significant decrease in brain cyst count versus group IV. As regards the histopathological examination of brain sections, after 7 and 14 days, group I showed the least histopathological inflammatory changes which was significantly lower than that of group IV. Group II revealed the most profound histopathological inflammatory changes. Group III showed mild to moderate inflammatory changes with a non-significant difference from group IV. As regards the survival rate, the group I showed the highest, group II showed the lowest mean survival time, which was statistically significant versus group IV. Group III showed a non-significant difference versus group IV. Conclusion: MSCs have an anti-inflammatory effect and prolong the survival of T. gondii infected mice; however, they have a non
View on SCiNiTO
Top